|
[1] European Association for the Study of the Liver. EASL clinical practice guidelines for the management of patients with decompensated cirrhosis[J]. J Hepatol,2018,69(2):406-460.
|
|
[2] Chinese Society of Hepatology,Chinese Medical Association,XU X,et al. Chinese guidelines on the management of ascites and its related complications in cirrhosis[J]. Hepatol Int,2019,13(1):1-21.
|
|
[3] Chinese Society of Hepatology,Chinese Medical Association.Chinese guidelines on the management of liver cirrhosis[J]. J Clin Hepatol,2019,35(11):2408-2425.(in Chinese)中华医学会肝病学分会．肝硬化诊治指南[J]．临床肝胆病杂志，2019,35(11):2408-2425.
|
|
[4] YANG HR. Value of color Doppler ultrasound in the diagnosis of portal hypertension liver cirrhosis merged with esophageal variceal bleeding[J]. J Hainan Med Univ,2016,22(5):496-498.(in Chinese)杨海荣．彩色多普勒超声在肝硬化门脉高压食管静脉曲张破裂出血中的价值[J]．海南医学院学报，2016,22(5):496-498.
|
|
[5] QI X,BERZIGOTTI A,CARDENAS A,et al. Emerging noninvasive approaches for diagnosis and monitoring of portal hypertension[J]. Lancet Gastroenterol Hepatol,2018,3(10):708-719.
|
|
[6] de FRANCHIS R,DELL'ERA A,PRIMIGNANI M. Diagnosis and monitoring of portal hypertension[J]. Dig Liver Dis,2008,40(5):312-317.
|
|
[7] HANNA RF,AGUIRRE DA,KASED N,et al. Cirrhosis-associated hepatocellular nodules:Correlation of histopathologic and MR imaging features[J]. Radiographics,2008,28(3):747-769.
|
|
[8] PALANIYAPPAN N,COX E,BRADLEY C,et al. Non-invasive assessment of portal hypertension using quantitative magnetic resonance imaging[J]. J Hepatol,2016,65(6):1131-1139.
|
|
[9] MILLER L,BANSON FL,BAZIR K,et al. Risk of esophageal variceal bleeding based on endoscopic ultrasound evaluation of the sum of esophageal variceal cross-sectional surface area[J]. Am J Gastroenterol,2003,98(2):454-459.
|
|
[10] LI S,ZHANG DF,LU W,et al. The predictive value of endoscopic ultrasound for the or the recurrence of esophageal varices after endo-scopic sophageal varix ligation[J]. Chin J Dis Endosc,2016,33(4):223-228.(in chinese)李爽，张德发，陆伟，等．超声内镜对食管静脉曲张套扎术后复发的预测作用[J]．中华消化内镜杂志，2016,33(4):223-228.
|
|
[11] MCCOLLOUGH CH,LENG S,YU L,et al. Dual-and multienergy CT:Principles,technical approaches,and clinical applications[J]. Radiology,2015,276(3):637-653.
|
|
[12] FORNER A,REIG M,BRUIX J. Hepatocellular carcinoma[J].Lancet,2018,391(10127):1301-1314.
|
|
[13] Bureau of Medical Administration,National Health Commission of the People’s Republic of China. Guidelines for diagnosis and treatment of primary liver cancer in China(2019 edition)[J]. J Clin Hepatol,2020,36(2):277-292.(in Chinese)中华人民共和国国家卫生健康委员会医政医管局．原发性肝癌诊疗规范(2019年版)[J]．临床肝胆病杂志，2020,36(2):277-292.
|
|
[14] VILLANUEVA A. Hepatocellular carcinoma[J]. N Engl J Med,2019,380(15):1450-1462.
|
|
[15] RENZULLI M,BISELLI M,BROCCHI S,et al. New hallmark of hepatocellular carcinoma,early hepatocellular carcinoma and high-grade dysplastic nodules on Gd-EOB-DTPA MRI in patients with cirrhosis:A new diagnostic algorithm[J]. Gut,2018,67(9):1674-1682.
|
|
[16] MARRERO JA,KULIK LM,SIRLIN CB,et al. Diagnosis,staging, and management of hepatocellular carcinoma:2018Practice Guidance by the American Association for the Study of Liver Diseases[J]. Hepatology,2018,68(2):723-50.
|
|
[17] ZHOU XM,LIU CC,ZHOU W,et al. An excerpt of ACR appropriateness criteria chronic liver disease(2017)[J]. J Clin Hepatol,2018,34(1):44-45.(in Chinese)周新苗，刘长春，周巍，等．《2017年美国放射学会慢性肝病放射诊断的适用标准》摘译[J]．临床肝胆病杂志，2018,34(1):44-45.
|
|
[18] ROBERTS LR,SIRLIN CB,ZAIEM F,et al. Imaging for the diagnosis of hepatocellular carcinoma:A systematic review and meta-analysis[J]. Hepatology,2018,67(1):401-421.
|
|
[19] PARK JW,KIM JH,KIM SK,et al. A prospective evaluation of18F-FDG and 11C-acetate PET/CT for detection of primary and metastatic hepatocellular carcinoma[J]. J Nucl Med,2008,49(12):1912-1921.
|
|
[20] LIN CY,CHEN JH,LIANG JA,et al.18F-FDG PET or PET/CT for detecting extrahepatic metastases or recurrent hepatocellular carcinoma:A systematic review and meta-analysis[J]. Eur J Radiol,2012,81(9):2417-2422.
|
|
[21] BELLAARD R,DELGADO-BOLTON R,OYEN WJ,et al.FDG PET/CT:EANM procedure guidelines for tumour imaging:version 2. 0[J]. Eur J Nucl Med Mol Imaging,2015,43(2):328-354.
|
|
[22] NA SJ,OH JK,HYUN SH,et al.(18)-FDG PET/CT can prediat surival of advanced hepatocellular carcinoma patients:A multicenter retrospective cohort study[J]. J Nucl Mecl,2017,58(5):730-736.
|
|
[23] HECTORS SJ,WAGNER M,BESA C,et al. Multiparametric FDG-PET/MRI of hepatocellular carcinoma:Initial experience[J]. Contrast Media Mol Imaging,2018,2018:5638283.
|
|
[24] MARGINI C,BERZIGOTTI A. Portal vein thrombosis:The role of imaging in the clinical setting[J]. Dig Liver Dis,2017,49(2):113-120.
|
|
[25] SARIN SK,PHILIPS CA,KAMATH PS,et al. Toward a comprehensive new classification of portal vein thrombosis in patients with cirrhosis[J]. Gastroenterology,2016,151(4):574-577,e3.
|
|
[26] SHIMADA K,ISODA H,OKADA T,et al. Non-contrast-enhanced MR portography with time-spatial labeling inversion pulses:Comparison of imaging with three-dimensional halffourier fast spin-echo and true steady-state free-precession sequences[J]. J Magn Reson Imaging,2009,29(5):1140-1146.
|
|
[27] FURUTA A,ISODA H,YAMASHITA R,et al. Non-contrastenhanced MR portography with balanced steady-state freeprecession sequence and time-spatial labeling inversion pulses:Comparison of imaging with flow-in and flow-out methods[J]. J Magn Reson Imaging,2014,40(3):583-587.
|
|
[28] OHNO T,ISODA H,FURUTA A,et al. Non-contrast-enhanced MR portography and hepatic venography with timespatial labeling inversion pulses:Comparison at 1. 5 Tesla and3 Tesla[J]. Acta Radiol Open, 2015, 4(5):2058460115584110.
|
|
[29] LYU Y,HAN GH,FAN DM. Research progress of portal vein thrombosis in patients with liver cirrhosis[J]. Chin J Dig,2017,37(8):568-570.(in chinese)吕勇，韩国宏，樊代明．肝硬化门静脉血栓研究进展[J]．中华消化杂志，2017,37(8):568-570.
|
|
[30] SAPISOCHIN G,BRUIX J. Liver transplantation for hepatocellular carcinoma:Outcomes and novel surgical approaches[J]. Nat Rev Gastroenterol Hepatol,2017,14(4):203-217.
|
|
[31] LLOVET JM,PAVEL M,RIMOLA J,et al. Pilot study of living donor liver transplantation for patients with hepatocellular carcinoma exceeding Milan Criteria(Barcelona Clinic Liver Cancer extended criteria)[J]. Liver Transpl,2018,24(3):369-379.
|
|
[32] SPOSITO C,CUCCHETTI A,MAZZAFERRO V. Assessing competing risks for death following liver transplantation for hepatocellular carcinoma[J]. Dig Dis Sci,2019,64(4):1001-1007.
|
|
[33] ROSSANO G,MARTINA P,GIUSEPPE C,et al. Imaging of liver transplantation[J]. Eur J Radiol,2017,93:295-307.
|
|
[34] GIROMETTI R,PANCOT M,COMO G,et al. Imaging of liver transplantation[J]. Eur J Radiol,2017,93:295-307.
|
|
[35] RENNET J,DORNIA C,GEORGIEVA M,et al. Identification of early complications following liver transplantation using contrast enhanced ulrasound(CEUS),First results[J]. J Gastrointesti Liver Dis,2012,21:407-412.
|
|
[36] WANG WP,HUANG BJ,DING H,et al. Preliminary application of contrast-enhanced ultrasound in detecting hepatic arterial embolization in liver transplantation[J]. Shanghai med imaging technol,2006,15(4):272-273.(in Chinese)王文平，黄备建，丁红，等．超声造影在检测移植肝肝动脉栓塞中的初步应用[J]．上海医学影像技术，2006,15(4):272-273.
|
|
[37] HWANG J,KIM YK,JEONG WK,et al. Nonhypervascular hypointense nodules at gadoxetic acid-enhanced MR imaging in chronic liver disease:Diffusion-weighted imaging for characterization[J]. Radiology,2015,276(1):137-146.
|
DownLoad: